IOSP trades 39.0% below Wall Street's consensus target of $115.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes IOSP achieves its forward estimates and maintains a stable P/E multiple of 17.1x. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, Innospec Inc. (IOSP) has a Wall Street consensus price target of $115.00, based on estimates from 9 covering analysts. With the stock currently trading at $82.73, this represents a potential upside of +39.0%. The company has a market capitalization of $2.04B.
Analyst price targets range from a low of $115.00 to a high of $115.00, representing a 0% spread in expectations. The median target of $115.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 4 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, IOSP trades at a trailing P/E of 17.7x and forward P/E of 17.1x. The forward PEG ratio of 0.53 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +5.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $89.33, with bear and bull scenarios of $56.28 and $117.70 respectively. Model confidence stands at 50/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
HWKNHawkins, Inc. | $3.4B | $161.45 | — | — | Buy | 41.0x | 1 |
BCPCBalchem Corporation | $5.3B | $165.92 | $175.50 | +5.8% | Buy | 31.7x | 10 |
ITICInvestors Title Company | $488M | $258.38 | — | — | — | 42.5x | — |
KWRQuaker Chemical Corporation | $2.6B | $150.18 | $176.75 | +17.7% | Buy | 21.4x | 14 |
CBTCabot Corporation | $4.8B | $91.80 | $86.00 | -6.3% | Buy | 14.5x | 15 |
ASIXAdvanSix Inc. | $535M | $19.86 | $22.00 | +10.8% | Buy | 13.8x | 6 |
ALBAlbemarle Corporation | $18.9B | $160.35 | $209.75 | +30.8% | Hold | 13.2x | 45 |
ECLEcolab Inc. | $76.0B | $269.12 | $326.91 | +21.5% | Buy | 32.4x | 37 |
IFFInternational Flavors & Fragrances Inc. | $19.6B | $76.72 | $88.13 | +14.9% | Buy | 17.3x | 33 |
TROXTronox Holdings plc | $1.2B | $7.40 | $8.33 | +12.6% | Buy | — | 17 |
Quick answers to the most common questions about buying IOSP stock.
The consensus Wall Street price target for IOSP is $115, representing 39.0% upside from the current price of $82.73. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
IOSP has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $115 implies 39.0% upside from current levels.
With a forward P/E of 17.1284x, IOSP trades at a relatively low valuation. The consensus target of $115 implies 39.0% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $115 for IOSP, while the most conservative target is $115. The consensus of $115 represents the median expectation. Our quantitative valuation model projects a bull case target of $118 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
IOSP is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IOSP stock forecast based on 9 Wall Street analysts shows a consensus price target of $115, with estimates ranging from $115 (bear case) to $115 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $89, with bear/bull scenarios of $56/$118.
Our quantitative valuation model calculates IOSP's fair value at $89 (base case), with a bear case of $56 and bull case of $118. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 50/100.
IOSP trades at a forward P/E ratio of 17.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 17.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on IOSP, with a "Hold" consensus rating and $115 price target (39.0% upside). 4 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IOSP analyst price targets range from $115 to $115, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $115 consensus represents the middle ground. Our model's $56-$118 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.